If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Mallard Acquisition (MACUU)
MingZhu Logistics Holdings (YGMZ)
Good Works Acquisition (GWACU)
Bull Horn Holdings (BHSEU)
Decarbonization Plus Acquistion (DCRBU)
Horizon Acquisition II (HZON.U)
Helix Acquisition (HLXA)
Datto Holding Corp. (MSP)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Foghorn Therapeutics Inc. (FHTX)
Gatos Silver, Inc. (GATO)
Priced IPO
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
fuboTV Inc. (FUBO)
Presidio Property Trust (SQFT)
Academy Sports and Outdoors, Inc. (ASO)
Immunome Inc. (IMNM)
C4 Therapeutics, Inc. (CCCC)
Oncorus, Inc (ONCR)
More companies

CureVac B.V. (CVAC)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Their vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. Messenger ribonucleic acid, or mRNA, plays a central role in cellular biology in the production of proteins in every living cell. They are the pioneers in successfully harnessing mRNAs designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Their technology platform is based on a natural approach to optimize mRNA constructs that encode functional proteins that replace defective or missing proteins using the cell’s intrinsic translation machinery. Their current product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Their lead clinical programs are CV8102, which they are evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which they are currently investigating in a Phase 1 clinical trial for potential vaccination against rabies. They are also rapidly advancing their mRNA vaccine program against coronavirus (SARS-CoV-2), for which they initiated a Phase 1 clinical trial in healthy volunteers in June 2020, with results expected in the fourth quarter of 2020.
Franz-Werner Haas Pierre Kemula
Employees Founded
484 2000


Address: Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany

Telephone: +49 7071 9883 0

Web page:

IPO information

Expected Date 8/14/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $2647.5
Revenues (MM) $17.4
Net Income (Loss) (MM) $-102.4


What do you think will happen with the CVAC share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 13.3
Shares Revised (MM) 13.3
Expected offer amount (MM) $199.5
Realized offer amount(MM) $212.8
BofA Securities/ Jefferies/ Credit Suisse
Kempen & Co

Sector: Healthcare

Tweets about $CVAC

Tweets volume:

RT volume:


Google Trends Stats